Xenical Rx-To-OTC Switch Filing Slated For This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
A 2005 filing for over-the-counter sale of the obesity agent would be one year earlier than previously expected. GlaxoSmithKline has conducted double-blind, placebo-controlled trials with an orlistat 60 mg dose and has received “good encouragement” from FDA, CEO Garnier says.